Home
Biopharma partnerships

Biopharma partnerships

NeoGenomics offers unparalleled services to accelerate your complex drug development program and clinical trials, supported by a network
of College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories.

Pharma Services Client Portal

What makes us different

At NeoGenomics, we understand the needs of pharmaceutical and biotechnology companies, and we align with our partners to support development of therapies that will save lives. With over a decade of experience, we are a trusted partner in oncology research and development, delivering solutions to advance your drug development and clinical trial programs for targeted therapies and emerging treatment modalities.

No matter the scale or business need, we deliver:

Rapid project initiation with flexible, scalable support for evolving study needs
Immediate access to experienced MDs, PhDs, and a dedicated project manager, ensuring project integrity
Available regulatory and quality experts to support our pharma and biotech partners
Certified pathology staff capable of performing US Food and Drug Administration (FDA)-approved companion diagnostic confirmations

Seamless end-to-end multi-modal solutions, eliminating the need for multiple vendors
Broad pharmaceutical test menu and integrated data analysis
Customized solutions to accelerate your development program

Lab services

Cell therapy solutions

Antibody-drug conjugates (ADCs) solutions

Biomarker solutions

Lab services

Comprehensive lab service offerings

Whether you need a standard off-the-shelf assay from our robust testing menu or prefer to have tailored solutions, we can help. Our regulatory, quality, and operational expertise ensures that you can fast-track your critical milestones.

Anatomic pathology and immunohistochemistry
Anatomic pathology and immunohistochemistryBroad anatomic pathology and histology services to support your drug development and clinical trials
Genomics and sequencing
Genomics and sequencingComprehensive sequencing services, including next-generation sequencing (NGS), quantitative polymerase chain reaction (qPCR), real-time polymerase chain reaction (RT-PCR), droplet digital polymerase chain reaction (ddPCR), and Sanger sequencing
Flow cytometry
Flow cytometryGain insight into immunophenotyping and functional biomarkers with advanced flow cytometry panels
Spatial analysis
Spatial analysisSpatial tissue analysis for a complete interrogation of the tumor microenvironment and advancement of biomarker discovery
Fluorescence in situ hybridization (FISH) & cytogenetics
FISH & cytogeneticsHolistic solutions for accessing constitutional and acquired chromosomal aberrations
Immunoassays
ImmunoassaysMultiplexed immunoassays to detect protein of interest

Move your drug development and clinical trials forward, faster.

Cell therapy solutions

Fast-track your cell therapy program and clinical trials breakthroughs

We understand the need of pharmaceutical and biotechnology companies to harness the power of cell therapies in the fight against cancer. Our comprehensive suite of cell therapy multi-modality testing solutions leverage over a decade of experience, including participation in more than 1,500 clinical trials in the past 5 years. Partner with us to unlock your next cell therapy innovation.

CAR-T solution

Antibody-drug conjugates (ADCs) solutions

ADC development made easier than ever

Leverage our deep scientific expertise for seamless antibody-drug conjugate (ADC) development. Our dedicated MDs and PhDs provide expert guidance tailored to your research and business needs and help you achieve critical milestones faster.

Biomarker solutions

Propel your drug development with groundbreaking biomarker insights

Recent advances have shifted the focus from traditional therapies to precision medicine, driven by the strategic use of biomarkers. These essential tools accelerate the discovery, development, and approval of new drugs, enabling faster delivery of more innovative treatments while adding significant value to development programs. Our specialized team enables pharmaceutical partners with actionable insights to drive informed decisions and accelerate biomarker development.

Clinical trial optimization

Clinical trials are becoming increasingly complex, with each study presenting unique challenges and nuances. As a rapidly growing oncology-specific clinical research organization (CRO), NeoGenomics partners with biopharma companies to deliver the insights they need. Backed by a dedicated clinical trial team, we ensure that your study objectives are met on time.

Regulatory support

NeoGenomics delivers thoughtful oversight to ensure compliance with federal regulations for a successful commercial launch. We provide in-house regulatory and compliance support to our pharma and biotech partners to support their clinical trial requirements, and we have enjoyed a 100% success rate with institutional review board (IRB) and FDA submissions,* often receiving consistent favorable FDA feedback.

More info on regulatory support

*Data on file.

Companion diagnostics

The use of biological signatures to identify patients who are likely to benefit from a particular therapy has greatly accelerated the pace of drug development and approval. Simultaneously, it has complicated drug development by requiring the co-development of a companion diagnostic (CDx) assay to accurately and reproducibly select patients who are likely to benefit from said therapy. We provide specialized scientific expertise to ensure CDx success and accelerate your pipeline progress.

Commercialization support

We are pleased to offer complete end-to-end support throughout the commercialization process. NeoGenomics is one of the largest oncology-focused laboratories in the United States, with established relationships with major in vitro diagnostic (IVD) providers, single-site FDA-approved test approvals, and partnerships for ex-US launch needs.

Oncology data solutions

Our commitment to advancing cancer care with real-world multi-modal oncology data solutions makes us a valuable partner to pharmaceutical companies.

Understanding the vital role that data play in precision oncology, NeoGenomics has the scientific expertise and innovation to help pharma companies succeed sooner.

Partner testimonials

The technologies offered at NeoGenomics had advantages over other CROs we explored, including the ability to obtain high-quality RNA sequencing data from challenging starting materials such as formalin-fixed paraffin-embedded (FFPE) material and the ability of MultiOmyx® technology to measure multiple markers within a single FFPE slide, while avoiding the issue of spectral overlap that arises from more traditional immunofluorescence approaches.

— Infinity Pharmaceuticals

The NeoGenomics team has the technical expertise to develop and qualify novel multiplexing assays to support preclinical and clinical testing of samples from clinical studies to the highest standards. The technical team has been very collaborative and interactive with the IAVI team and paid close attention to the client’s requirements.

— IAVI

Resources and publications

Review our variety of publications, poster presentations, and white papers.

Sign up for PharmaConnect

Want to learn more about NeoGenomics’ pharma services? Sign up to receive our quarterly newsletter, PharmaConnect.

Become a NeoGenomics partner

Join the growing list of renowned pharma companies who have developed winning partnerships with NeoGenomics to advance their research and business needs. Contact us to learn more.